Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 5:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 2,413 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Laboratory testing Clear all
Active, not recruiting Phase 2 Interventional

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

NCT03919071
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified, Anaplastic Ganglioglioma, Anaplastic Pleomorphic Xanthoastrocytoma, Glioblastoma, Malignant Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma
Interventions
Biospecimen Collection, Dabrafenib Mesylate, Lumbar Puncture, Magnetic Resonance Imaging, Radiation Therapy, Trametinib Dimethyl Sulfoxide
Procedure · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 25 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
130
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 106 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 27, 2026, 5:23 AM EDT
Completed Not applicable Interventional

Blood Volume and Hemodynamic Analysis in Patients With Chronic Heart Failure

NCT02120014
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
blood volume measurement, venous plethysmography
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 27, 2026, 5:23 AM EDT
Completed No phase listed Observational

Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Non-Metastatic, Post Menopausal Breast Cancer Patients

NCT01051609
View directory record Official record
Conditions
Breast Cancer
Interventions
History and Physical Exam, Grip Strength Measurement, Surveys, Blood Collection, Ultrasound of Hand/Wrist
Other · Behavioral · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 27, 2026, 5:23 AM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

NCT05092958
View directory record Official record
Conditions
Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Advanced Urethral Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis and Ureter Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis and Ureter Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8
Interventions
Avelumab, Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
271
States / cities
Phoenix, Arizona • Auburn, California • Berkeley, California + 214 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 27, 2026, 5:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assessing Visual Processing in High Anxiety

NCT04187326
View directory record Official record
Conditions
Anxiety
Interventions
Facial Microexpression Training
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 30 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 27, 2026, 5:23 AM EDT
Completed No phase listed Observational

HIV, Buprenorphine, and the Criminal Justice System (STRIDE2)

NCT03583138
View directory record Official record
Conditions
Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, Opiate Addiction, Drug Dependence
Interventions
buprenorphine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Oct 27, 2026, 5:23 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)

NCT06351371
View directory record Official record
Conditions
Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Erdafitinib, Magnetic Resonance Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 27, 2026, 5:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Development of a Novel Method to Measure Insulin Sensitivity in Humans: A Pilot Study

NCT04774081
View directory record Official record
Conditions
Insulin Sensitivity
Interventions
24h Continuous glucose monitoring and urinary C-peptide collection
Device
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 27, 2026, 5:23 AM EDT
Terminated No phase listed Observational

Adult MDW Dual Cut-Off Accuracy Study

NCT06885528
View directory record Official record
Conditions
Sepsis
Interventions
Complete Blood Count with differential
Diagnostic Test
Lead sponsor
Beckman Coulter, Inc.
Industry
Eligibility
18 Years to 89 Years
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Indianapolis, Indiana • Kansas City, Kansas • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 27, 2026, 5:23 AM EDT
Completed No phase listed Observational

DNA Analysis of Tumor Tissue Samples From Young Patients With Acute Lymphoblastic Leukemia

NCT00897507
View directory record Official record
Conditions
Childhood Acute Lymphoblastic Leukemia in Remission, Recurrent Childhood Acute Lymphoblastic Leukemia
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 18 Years
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Oct 27, 2026, 5:23 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Home-Based Respiratory Muscle Training and Aerobic Exercise Programs to Improve Lung Health in Current and Former Cigarette Smokers

NCT07553819
View directory record Official record
Conditions
Lung Carcinoma
Interventions
Accelerometry, Aerobic Exercise, Biospecimen Collection, Educational Intervention, Electronic Health Record Review, Physical Performance Testing, Respiratory Muscle Training, Supportive Care, Survey Administration
Procedure · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
50 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 27, 2026, 5:23 AM EDT
Completed No phase listed Observational

Early Detection and Prediction of Chemotherapy Induced Cardiac Toxicity in Breast Cancer Patients

NCT00806507
View directory record Official record
Conditions
Breast Cancer
Interventions
Echocardiograms, Blood Test
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2012 · Synced Oct 27, 2026, 5:23 AM EDT
Recruiting Phase 1 Interventional

FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT06609928
View directory record Official record
Conditions
Recurrent Childhood Acute Myeloid Leukemia, Refractory Childhood Acute Myeloid Leukemia
Interventions
FOLR1 CAR T-cells, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Echocardiography Test, Fludarabine, Pheresis, Positron Emission Tomography
Biological · Procedure · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 6 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2042
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 27, 2026, 5:23 AM EDT
Recruiting Phase 1 Interventional

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

NCT05989828
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Aldesleukin, Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes, Biopsy, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Leukapheresis, Magnetic Resonance Imaging, Mammogram, Multigated Acquisition Scan, Ultrasound Imaging
Biological · Procedure · Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 27, 2026, 5:23 AM EDT
Enrolling by invitation Not applicable Interventional

EVOLV-Rx VA: Evaluating Opportunities to Decrease Low-Value Prescribing in Community Living Centers

NCT07166107
View directory record Official record
Conditions
Low-Value Care
Interventions
EVOLV-Rx dashboard
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years and older
Enrollment
1,161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania • Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 27, 2026, 5:23 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer

NCT07281599
View directory record Official record
Conditions
HPV Infection, HPV 16 Infection, High Risk HPV, Cervical Cancer Screening, Cervical Cancer Cin Grade, Cervical Cancer (Early Detection), HPV, HPV (Human Papillomavirus)-Associated, HPV DNA, HPV Infections, Screening Test
Interventions
Q-Pad hrHPV Test System
Device
Lead sponsor
Qurasense
Industry
Eligibility
25 Years and older · Female only
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
New Haven, Connecticut • Minneapolis, Minnesota • Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 27, 2026, 5:23 AM EDT
Completed Not applicable Interventional Results available

IMPROVE AKI Cluster-Randomized Trial

NCT03556293
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
AKI Prevention Toolkit, Technical Assistance (TA), Virtual Learning Collaborative (VLC), Automated Surveillance Reporting (ASR)
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
Not listed
Enrollment
10,252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Nashville, Tennessee • White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 27, 2026, 5:23 AM EDT
Completed Not applicable Interventional

Respiratory Disorders Non-invasive Monitoring of Work of Breathing in Outpatients

NCT04003415
View directory record Official record
Conditions
Copd, Asthma, Respiratory Effort, Contactless Vital Sign Monitoring
Interventions
Investigational Device: Contactless heart rate and respiratory rate monitor, Heart Rate (EKG) Monitor, Respiratory rate Monitor, Pulse Oximetry
Device · Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 27, 2026, 5:23 AM EDT
Completed Not applicable Interventional

Genomic Opioid Optimization of Dosing and Selections (GOODS) Study

NCT03579121
View directory record Official record
Conditions
Perioperative/Postoperative Complications
Interventions
Pharmacogenomic (PGx), Review results
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 27, 2026, 5:23 AM EDT
Completed Not applicable Interventional Results available

Rapid Diagnostics for Upper Respiratory Infections in the Emergency Department

NCT02957136
View directory record Official record
Conditions
Respiratory Tract Infections, Influenza, Human, Common Cold
Interventions
Rapid respiratory pathogen nucleic acid amplification test
Device
Lead sponsor
University of California, Davis
Other
Eligibility
1 Year to 101 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 27, 2026, 5:23 AM EDT
Recruiting Phase 2 Interventional

Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy

NCT06930352
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cytarabine, Echocardiography Test, Hydroxyurea, Leukapheresis, Multigated Acquisition Scan, Questionnaire Administration, Ziftomenib
Procedure · Drug · Other
Lead sponsor
Uma Borate
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 27, 2026, 5:23 AM EDT
Completed Not applicable Interventional

A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program

NCT02297126
View directory record Official record
Conditions
Adverse Drug Reaction
Interventions
Pharmacogenetic Intervention Arm (pharmacogenetic testing)
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4,465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 27, 2026, 5:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Newborn Genomic Sequencing Pilot Study

NCT06276348
View directory record Official record
Conditions
Genetic Disease
Interventions
Whole genome sequencing, BeginNGS test, WES
Genetic
Lead sponsor
Rady Pediatric Genomics & Systems Medicine Institute
Other
Eligibility
1 Day to 10 Days
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 27, 2026, 5:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

NCT02858310
View directory record Official record
Conditions
Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms, Vulvar Diseases
Interventions
E7 TCR cells, Aldesleukin, Fludarabine, Cyclophosphamide, EKG, Biopsy, Chest CT and MRI or PET, PFT, Granisetron, Ondansetron, Droperidol, Prochlorperazine, Diphenoxylate HCL, Atropine sulfate, Codeine sulfate, Loperamide, Indomethacin, Acetaminophen, Diphenhydramine HCL, Hydroxyzine HCL, Meperidine
Biological · Drug · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Bethesda, Maryland • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 27, 2026, 5:23 AM EDT